Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
Upfront IDH1 Inhibitor Triples Survival in Older AML Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-T Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patients Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
Pegylated Interferon Wins FDA Approval for Polycythemia Vera Majority of patients attained complete hematologic response with ropeginterferon alfa-2b Nov 15, 2021
A Gentler Standard for Acute Promyelocytic Leukemia in Kids ATRA/arsenic trioxide without maintenance therapy resulted in 99-100% survival at 2 years Nov 11, 2021
FDA Approves STAMP Inhibitor for Chronic Myeloid Leukemia Patients treated with two or more TKIs and those with T315I mutation gain new option Nov 01, 2021
What Happens When All the Great Doctors Are Gone? In commemoration of the late Elihu (Eli) Estey, MD Oct 13, 2021
Life Expectancy Still Lower for Blood or Marrow Transplant Recipients Although late mortality has decreased over the past 40 years Sep 09, 2021
Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia Complete responses in 18 of 20 patients with relapsed/refractory T-cell ALL Aug 04, 2021
Add-On Venetoclax Promising in Younger, Fit AML Patients "Safe and feasible intensive regimen" in small single-center study Jul 30, 2021
IVF Babies at No Increased Risk of Childhood Cancers No associations seen with intracytoplasmic sperm injection or frozen embryo transfer, study found Jul 02, 2021
Ethics Consult: Help Family Have 'Savior Child' for Marrow Donation? MD/JD Weighs In You voted, now see the results and an expert's discussion Jun 25, 2021
Fixed-Duration, All-Oral Regimen Slows CLL Progression Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil Jun 16, 2021
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor Jun 14, 2021
COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
Acalabrutinib Offers Less Wear and Tear on the Heart in CLL Patients BTK inhibitor had less cardiotoxicity than ibrutinib, but similar efficacy Jun 07, 2021
CAR-T Drives High Response in Relapsed/Refractory ALL ZUMA-3 study shows brexucabtagene autoleucel offers long-term clinical benefit Jun 06, 2021
Combination Therapy Achieves High Response in Ph+ ALL Ponatinib-blinatumomab offers promising regimen in frontline and relapse/refractory disease Jun 05, 2021
Combo Therapy Boosts Response in Hairy Cell Leukemia Complete response achieved in 26 of 30 patients with vemurafenib/rituximab May 12, 2021
Op-Ed: Blood Cancer Patients Need More COVID Vax Answers Patients are left wondering, "will I be protected?" Mar 24, 2021
Whole-Genome Sequencing Makes a Case in Leukemia Study More actionable alterations detected in myeloid malignancies versus cytogenetics Mar 10, 2021
Study Confirms Risk-Adapted CRS Prophylaxis for Acute Leukemia Tocilizumab reduced severe cytokine release syndrome in children, young adults Mar 09, 2021
Ethics Consult: Refuse Treatment for Dictator? MD/JD Weighs In You voted, now see the results and an expert's discussion Jan 15, 2021
PARP Inhibitors Linked With Blood Cancer Risk Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden Dec 28, 2020
Chemo-Free Combo Boosts PFS in First-Line CLL PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting Dec 08, 2020
Novel Agent Active in Refractory CML Asciminib doubles molecular response versus bosutinib after two or more prior lines of therapy Dec 08, 2020
Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLL DFS at 1 year reaches 95% in patients with undetectable MRD Dec 06, 2020
Blood Cancers and COVID-19: 'A Medically Vulnerable' Group Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death Dec 06, 2020
These Forbes 400 Billionaires Made Their Fortunes in Healthcare 14 individuals, $66 billion in combined net worth Sep 24, 2020
Raising the Bar for Myelofibrosis Therapy Development Rational combinations, new targets, and a first-ever phase III trial with a survival endpoint Sep 14, 2020
Worse Blood Cancer Outcomes in Hispanics Diagnosis at earlier age, worse survival, especially for those on U.S.-Mexico border Jun 24, 2020
Combination Ups Survival in Older AML Patients Frontline venetoclax plus azacitidine adds 5 months to median OS versus azacitidine alone Jun 17, 2020
Early Palliation: Boon for AML Patients on Intensive Chemo Intervention led to marked improvements in QoL, mental distress, end-of-life care Jun 02, 2020
COVID-19 Mortality Spikes in Patients With Lung, Blood Cancers Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
Bringing Transplant to More Patients With AML Conditioning with radiolabeled antibody leads to successful transplantation in 84% of older patients Feb 25, 2020
New CAR-T Makes Case for Aggressive Lymphomas Largest trial to date shows 73% ORR, 53% CR, potential for outpatient treatment Feb 25, 2020
